Non-antibacterial tetracycline formulations: Clinical applications in dentistry and medicine

Journal of Oral Microbiology

Volumn 4, Issue 2012, 2012, Pages 1-14

  Gu, Ying ^a   Walker, Clay ^b   Ryan, Maria E ^a   Payne, Jeffrey B ^c   Golub, Lorne M ^a  

^a Stony Brook School of Dental Medicine   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Clinical applications; Host modulation; Matrix metalloproteinase inhibitors; Tetracyclines

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CYTOKINE; DOXYCYCLINE; DOXYCYCLINE HYCLATE; FLURBIPROFEN; IMMUNOMODULATING AGENT; INCYCLINIDE; INDUCIBLE NITRIC OXIDE SYNTHASE; MATRIX METALLOPROTEINASE; METHOTREXATE; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTANOID; REACTIVE OXYGEN METABOLITE; RESOLVIN; TETRACYCLINE; UNCLASSIFIED DRUG;

ACNE; ACUTE HEART INFARCTION; ADJUVANT ARTHRITIS; ADULT RESPIRATORY DISTRESS SYNDROME; AGGRESSIVE PERIODONTITIS; ALPHA 1 ANTITRYPSIN DEFICIENCY; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; AORTA ANEURYSM; ARTHRITIS; ARTICLE; ATHEROSCLEROSIS; BACTERIAL COLONIZATION; BACTERIAL OVERGROWTH; BIOFILM; BULLOUS PEMPHIGOID; CARDIOVASCULAR DISEASE; CHEMICAL MODIFICATION; CHRONIC PERIODONTITIS; CLINICAL EFFECTIVENESS; CLINICAL STUDY; COLONY FORMING UNIT; CONCENTRATION RESPONSE; DENTISTRY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG APPROVAL; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG IDENTIFICATION; DRUG PENETRATION; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; ENZYME ACTIVITY; ENZYME INHIBITION; EPIDERMOLYSIS BULLOSA; GRANULOMATOSIS; HEART PROTECTION; HUMAN; HYPERTENSION; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY DISEASE; KAPOSI SARCOMA; LOW DRUG DOSE; LUNG DISEASE; LYMPHANGIOLEIOMYOMATOSIS; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PLASMA CONCENTRATION; MEDICINE; MINIMUM INHIBITORY CONCENTRATION; MOUTH INFLAMMATION; MUCOUS MEMBRANE PEMPHIGOID; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOPENIA; PANNICULITIS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PEMPHIGOID; PERIODONTAL DISEASE; PERIODONTITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PORPHYROMONAS GINGIVALIS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RARE DISEASE; RECOMMENDED DRUG DOSE; RHEUMATOID ARTHRITIS; ROSACEA; SARCOIDOSIS; SEPTIC SHOCK; SINGLE DRUG DOSE; SUSTAINED RELEASE FORMULATION; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84873375141     PISSN: None     EISSN: 20002297     Source Type: Journal    
DOI: 10.3402/jom.v4i0.19227     Document Type: Article

References (104)

1. Ivanyi LM, Wilton JMA, Lehner T. Cell mediated immunity in periodontal disease; cytotoxicity, migration inhibition and lymphocyte transformation studies. Immunology 1972; 22: 141-5.
2. Taubman MA, Yoshie H, Ebersole JL, Smith DJ, Olson CL. Host response in experimental periodontal disease. J Dent Res 1984; 63: 455-60.
3. Fullmer H, Gibson WA. Collagenolytic activity in gingivae of man. Nature (London) 1966; 209: 728-9.
4. Gross J, LaPiere CM. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci (USA) 1962; 48: 1014-21.
5. Ryan ME, Golub LM. Modulation of matrix metalloproteinase activity in periodontitis as a treatment strategy. Periodontology 2000; 24: 226-38.
6. Jeffcoat MK, Reddy MS, Haigh S, Buchanan W, Doyle MJ, Meredith MP, et al. A comparison of topical ketorolac, systemic flurbiprofen and placebo for the inhibition of bone loss in adult periodontitis. J Periodontol 1995; 66: 329-38.
7. Serhan CN. Controlling the resolution of acute inflammation: a new genus of dual anti inflammatory and proresolving mediators. J Periodontol 2008; 79: 1520-6.
8. Tenenbaum HC, Shelemay A, Girard B, Zohar R, Fritz PC. Bisphosphonates and periodontics: potential applications for regulation of bone mass in the periodontium and other therapeutic/diagnostic uses. J Periodontol 2002; 73: 813-22.
9. Caton J, Ryan ME. Clinical studies on the management of periodontal diseases utilizing subantimicrobial dose doxycycline (SDD). Pharmacolog Res 2011; 63: 114-20.
10. Golub LM, Ciancio S, Ramamurthy NS, Leung M, McNamara TF. Low dose doxycycline therapy: effect on gingival and crevicular fluid collagenase activity in humans. J Periodontal Res 1990; 25: 321-30.
11. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non antimicrobial mechanisms. Adv Dent Res 1998; 12: 2-26.
12. Ramamurthy NS, Zebrowski EJ, Golub LM. Collagenolytic activity of alloxan diabetic rat gingivae. Diabetes 1973; 22: 272-4.
13. Golub LM, Lee HM, Lehrer G, Nemiroff A, Mcnamara TF, Kaplan R, et al. Minocycline reduces gingival collagenolytic activity during diabetes: preliminary observations and a proposed new mechanism of action. J Periodontal Res 1983; 18: 516-6.
14. Golub LM, Greenwald RA, Ramamurthy NS, McNamara TF, Rifkin BR. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit Revs Oral Biol Med 1991; 2: 297-322.
15. Ryan ME, Ramamurthy NS, Sorsa T, Golub LM. MMPmediated events in diabetes. Ann NY Acad Sci 1999; 878: 311-34.
16. Golub LM, McNamara TF, D'Angelo G, Greenwald RA, Ramamurthy NS. A non antibacterial chemically modified tetracycline inhibits mammalian collagenase activity. J Dent Res 1987; 66: 1310-4.
17. Preshaw PM, Novak MJ, Mellonig J, Magnusson I, Polson A, Giannobile WV, et al. Modified release subantimicrobial dose doxycycline enhances scaling and root planing in subjects with periodontal disease. J Periodontol 2008; 79: 445-52.
18. Del Rosso JQ, Schlessinger J, Werschler P. Comparison of antiinflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drugs Dermatol 2008; 7: 573-6.
19. Skidmore R, Kovach R, Walker C, Thomas J, Bradshaw M, Leyden J, et al. Effects of sub antimicrobial dose doxycycline in the treatment of moderate acne. Arch Dermatol 2003; 139: 459-64.
20. Monk E, Shalita A, Siegel DM. Clinical applications of nonantimicrobial tetracyclines in dermatology. Pharmacolog Res 2011; 63: 130-45.
21. Dezube BJ, Krown SE, Lee JY, Bauer KS, Aboulafia DM. Randomized phase II trial of matrix metalloproteinase inhibitor COL 3 in AIDS related Kaposi's sarcoma: an AIDS malignancy consortium study. J Clin Oncol 2006; 24: 1389-93.
22. Richards C, Pantanowitz L, Dezube BJ. Antimicrobial and non antimicrobial tetracyclines in human cancer trials. Pharmacolog Res 2011; 63: 151-6.
23. Golub LM. Introduction and background, in special issue: clinical applications of non antibacterial tetracyclines. Pharmacolog Res 2011; 63: 97-156.
24. Carney DE, Lutz CJ, Picone AL, Gatto LA, Ramamurthy NS, Golub LM, et al. A matrix metalloproteinase inhibitor prevents acute lung injury after cardiopulmonary bypass. Circulation 1999; 100: 400-6.
25. Steinberg J, Gatto L, Schiller H, Lee HM, Halter J, Carney D, Golub L, et al. Chemically modified tetracycline prevents the development of septic shock and acute respiratory distress syndrome in a clinically applicable porcine model. Shock 2005; 24: 348-56.
26. Roy SK, Kubiak BD, Albert SP, Vieau CJ, Gatto L, Golub L, et al. Chemically modified tetracycline 3 prevents acute respiratory distress syndrome in a porcine model of sepsis plus ischemia/reperfusion lung injury. Shock 2012; 37: 424-32.
27. Zhang Y, Gu Y, Lee HM, Hambardjieva E, Vranková K, Golub LM et al. Design, synthesis and biologic activity of new polyenolic inhibitors of matrix metalloproteinases. Curr Med Chem 2012; in press.
28. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001; 65: 232-60.
29. Walker C, Thomas J, Nangó S, Lennon J, Wetzel J, Powala C. Long term treatment with sub antimicrobial dose doxycycline exerts no antibacterial effect on the subginigval microflora associated with adult periodontitis. J Periodontol 2000; 71: 1465-71.
30. Thomas J, Walker C. Long term use of subantimicrobial dose doxycycline does not lead to changes in antimicrobial susceptibility. J Periodontol 2000; 71: 1472-83.
31. Thomas JG, Metheny RJ, Karakiozis JM, Wetzel JM, Crout RL. Long term sub antimicrobial doxycycline (Periostat) as adjunctive management in adult periodontitis: effects on subgingival bacterial population dynamics. Adv Dent Res 1998; 12: 32-9.
32. Marsh P, Martin MV. Oral microbiology, 4th ed. Oxford: Wright; 1999, 115-7.
33. Preshaw PM, Hefti AH, Jepsen S, Etienne D, Walker C, Bradshaw MH. Subantimicrobial dose doxycycline as adjunctive treatment for periodontitis. A review. J Clin Periodontol 2004; 31: 697-707.
34. Walker C, Preshaw PM, Novak J, Hefti AH, Bradshaw M, Powala C. Long term treatment with sub antimicrobial dose doxycycline has no effect on the intestinal flora. J Clin Periodontol 2005; 32: 1163-9.
35. Skidmore R, Kovach R, Walker C, Thomas J, Bradshaw M, Leyden J, et al. Effects of subantimicrobial dose doxycycline in the treatment of moderate acne. J Fam Pract 2003; 52: 594-7.
36. Walker C, Puumala S, Golub LM, Stoner JA, Reinhardt RA, Lee H M, et al. Subantimicrobial dose doxycycline effects on osteopenic bone loss: microbiology results. J Periodontol 2007; 78: 1590-601.
37. Stoller NH, Johnson LR, Trapnell S, Harrold CQ, Garrett S. The pharmacokinetic profile of a biodegradable controlledrelease delivery system containing doxycycline compared to systemically delivered doxycycline in gingival crevicular fluid, saliva, and serum. J Periodontol 1998; 69: 1085-91.
38. Sedlacek M, Walker C. Antibiotic resistance in an in vitro subgingival biofilm model. Oral Microbiol Immunol 2007; 22: 333-9.
39. Donlan RM. Role of biofilms in antimicrobial resistance. ASAIO J 2000; 46: S47-52.
40. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002; 15: 167-93.
41. Mah TF, Pitts B, Pellock B, Walker GC, Stewart PS, O'Toole GA. A genetic basis for Pseaudomonas aerugionosa biofilm antibiotic reistance. Nature 2003; 426: 306-10.
42. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 2001; 358: 135-8.
43. Golub LM, Goodson JM, Lee HM, Vidal AM, McNamara TF, Ramamurthy NS. Tetracyclines inhibit tissue collagenases. Effects of ingested low dose and local delivery systems. J Periodontol 1985; 56: S93-7.
44. Lee HM, Cianci SG, Tuter G, Ryan ME, Komaroff E, Golub LM. Subantimicrobial dose doxycycline efficacy as a matrix metalloproteinase inhibitor is enhanced when combined with an NSAID. J Periodontol 2004; 75: 453-63.
45. Caton JG, Ciancio SG, Blieden TM, Bradshaw M, Crout RJ, Hefti AF, et al. Subantimicrobial dose doxycycline as an adjunct to scaling and root planing: post treatment effects. J Clin Periodontol 2001; 28(8): 782-9.
46. Emingil G, Gü rkan A, Atilla G, Kantarci A. Subantimicrobialdose doxycycline and cytokine chemokine levels in gingival crevicular fluid. J Periodontol 2011; 82: 452-61.
47. Eady EA, Cove JH, Holland KT, Cunliffe WJ. Superior antibacterial action and reduced incidence of bacterial resistance in minocycline compared to tetracycline treated acne patients. Br J Dermatol 1990; 122: 233-44.
48. Heimdahl A, Nord CE. Influence of doxycycline on the normal flora and colonization of the oral cavity and colon. Swed Dent J 1983; 7: 199-204.
49. Fiehn NE, Westergaard J. Doxycycline resistant bacteria in periodontally diseased individuals after resistant bacteria in periodontally diseases individuals after systemic doxycycline therapy and in healthy individuals. Oral Microbiol Immunol 1990; 5: 219-22.
50. Rams TE, Babalola OO, Slots J. Subgingival occurrence of enteric rods, yeasts and staphylococci after systemic doxycycline therapy. Oral Microbiol Immunol 1990; 5: 166-8.
51. Kornman KS, Karl EH. The effect of long term low dose tetracycline therapy on the subgingival microflora in refractory adult periodontitis. J Periodontol 1982; 3: 604-10.
52. Ashley RA. Clinical trials of a matrix metalloproteinase inhibitor in human periodontal disease. SDD clinical research team. Ann N Y Acad Sci 1999 30; 878: 335-46.
53. McNamara TF, Golub LM, Yu Z, Ramamurthy NS. Reduced doxycycline blood levels in humans fail to promote resistant organisms. In Conf on Periodont Disease: pathogenesis and host immune responses 1990; abstract #B54 (Conference Proceedings), Page 100, Osaka, Japan.
54. Barnett M. Changing paradigms in periodontal therapy: host modulation with subantimicrobial dose doxycycline. Oral Health 2007; 53-65.
55. Ciancio S, Ashley R. Safety and efficacy of sub antimicrobialdose doxycycline therapy in patients with adult periodontitis. Adv Dent Res 1998; 12: 27-31.
56. Payne JB, Golub LM. Using tetracyclines to treat osteoporotic/ osteopenic bone loss: from the basic science laboratory to the clinic. Pharmacol Res 2011; 63: 121-9.
57. Giannobile WV. Host response therapeutics for periodontal diseases. J Periodontol 2008; 79: S1592-600.
58. Reddy MS, Geurs NC, Gunsolley JC. Periodontal host modulation with antiproteinase, anti inflammatory, and bonesparing agents. A systematic review. Ann Periodontol 2003; 8: 12-37.
59. Preshaw PM, Hefti AF, Bradshaw MH. Adjunctive subantimicrobial dose doxycycline in smokers and non smokers with chronic periodontitis. J Clin Periodontol 2005; 32: 610-6.
60. Sgolastra F, Petrucci A, Gatto R, Giannoni M, Monaco A. Long term efficacy of subantimicrobial dose doxycycline as an adjunctive treatment to scaling and root planing: a systematic review and meta analysis. J Periodontol 2011; 82: 1570-81.
61. Novak MJ, Johns LP, Miller RC, Bradshaw MH. Adjunctive benefits of subantimicrobial dose doxycycline in the management of severe, generalized, chronic periodontitis. J Periodontol 2002; 73: 762-9.
62. Novak MJ, Dawson DR, Magnusson I, Karpinia K, Polson A, Ryan ME, et al. Combining host modulation and antimicrobial therapy in the management of moderate to severe periodontitis: a randomized, multi center trial. J Periodontol 2008; 79: 33-41.
63. Goldberg MB, Golub LM, Lee HM, Tenebaum HC. Assessing the effects of subantimicrobial dose doxycycline/flurbiprofen on refractory periodontal disease. J Den Res 2010; 89: abstract # 1176.
64. Cohen DM, Lee HM, Bhattacharyya I, Sensat ML, Payne JB, Golub LM. Effective treatment for cicatricial pemphigoid using a novel combination therapy. J Dent Res 2000; 79, 627.
65. Liu Z, Zhou X, Shapiro SD, Shipley JM, Twining SS, Diaz LA, et al. The serpin alpha1 proteinase inhibitor is a critical substrate for gelatinase B/MMP 9 in vivo. Cell 2000; 102: 647-55.
66. Weinberg MA. New applications of doxycycline hyclate in medicine and dentistry. US Pharmacist 2004.
67. Stechmiller J, Cowan L, Schultz G. The role of doxycycline as a matrix metalloproteinase inhibitor for the treatment of chronic wounds. Biol Res Nurs 2010; 11: 336-44.
68. Chin GA, Thigpin TG, Perrin KJ, Moldawer LL, Schultz GS. Treatment of chronic ulcers in diabetic patients with the topical metalloproteinase inhibitor, doxycycline. Wounds 2003; 15: 315-23.
69. Greenwald RA. The road forward: the scientific basis for tetracycline treatment of arthritic disorders. Pharmacolog Res 2011; 64: 610-3.
70. O'Dell JR, Elliott JR, Mallek JA, Mikuls TR, Weaver CA, Glickstein S, et al. Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone. Arth Rheum 2006; 54: 621-7.
71. Greenwald RA, Golub LM, Lavietes B, Ramamurthy NS, Gruber B, Laskin RS, et al. Tetracycline inhibit human synovial collagenase both in vitro and in vivo. J Rheumatol 1987; 14: 28-32.
72. Zernicke R, Wohl G, Greenwald RA, Moak SA, Leng W, Golub LM. Administration of systemic matrix metalloproteinase inhibitors maintains bone mechanical integrity in adjuvant arthritis. J Rheumatol 1997; 24: 1324-31.
73. Leung MK, Greenwald RA, Ramamurthy NS, Moak SA, Koszulinski R, Dieudonne D, et al. Tenidap and flurbiprofen enhance the uptake of matrix metalloproteinase inhibitor 4 dedimethyloamino tetracycline inflamed joints of adjuvant arthritic rats. J Rheumatol 1995; 22: 1726-31.
74. Brandt KD. Modification by oral doxycycline administration of articular cartilage breakdown in steoarthritis. J Rheumatol 1995; 43: 149-51.
75. Smith GN, Yu LP, Brandt KD, Capello WN. Oral administration of doxycycline reduces collagenase and gelatinase activities in extracts of human osteoarthritic cartilage. J Rheumatol 1998; 25: 532-5.
76. Israel HA, Ramamurthy NS, Greenwald RA, Golub LM. The potential role of doxycycline in the treatment of osteoarthritis of the temporomandibular joint. Adv Dent Res 1998; 12: 51-5.
77. Moses MA, Harper J, Folkman J. Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med 2006; 354: 2621-2.
78. Matsui K, Takeda K, Yu Z X, Travis WD, Moss J, Ferrans VJ. Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med 2000; 124: 267-75.
79. Engebretsen SP, Hey Hadavi J. Sub antimicrobial doxycycline for periodontitis reduces hemoglobin A1c in subjects with type 2 diabetes: a pilot study. Pharmacolog Res 2011; 64: 624-9.
80. Ryan ME, Ramamurthy NS, Golub LM. Tetracyclines inhibit protein glycation in experimental diabetes. Adv Dent Res 1998; 12: 152-8.
81. Golub LM, Ramamurthy NS, Llavaneras A, Ryan ME, Lee HM, Liu Y, et al. A chemically modified non antimicrobial tetracycline (CMT 8) inhibits gingival matrix metalloproteinases, periodontal breakdown, and extra oral bone loss in ovariectomized rats. Ann NY Acad Sci 1999; 878: 290-310.
82. Sasaki T, Ramamurthy NS, Golub LM. Tetracycline administration increases collagen synthesis in osteoblasts of diabetic rats: a quantitative autoradiographic study. Calc Tiss Int 1992; 50: 411-9.
83. Gomes BC, Golub LM, Ramamurthy NS. Tetracyclines inhibit parathyroid hormone induced bone resorption in tissue culture. Experentia 1984; 40: 1273-4.
84. Golub LM, Ramamurthy NS, McNamara TF, Gomes B, Wolff M, Casino A, et al. Tetracyclines inhibit tissue collagenase activity: a new mechanism in the treatment of periodontal disease. J Periodontal Res 1984; 19: 651-5.
85. Bain S, Ramamurthy NS, Impeduglia T, Scolman S, Golub LM, Rubin C. Tetracycline prevents cancellous bone loss and maintains near normal rates of bone formation in streptozotocin diabetic rats. Bone 1997; 21: 147-53.
86. Craig RG, Yu Z, Xu L, Barr R, Ramamurthy N, Boland J, et al. A chemically modified tetracycline inhibits streptozotocininduced diabetic depression of skin collagen synthesis and steady state type I procollagen Mrna. Biochim Biophys Acta 1998; 1402: 250-60.
87. Williams S, Wakisaka A, Zeng QQ, Barnes J, Martin G, Wechter WJ, et al. Minocycline prevents the decrease in bone mineral density and trabecular bone in ovariectomized aged rats. Bone 1996; 19: 637-44.
88. Williams S, Wakisaka A, Zeng QQ, Barnes J, Seyedin S, Martin G, et al. Effect of minocycline on osteoporosis. Adv Dent Res 1998; 12: 71-5.
89. Payne JB, Reinhardt RA, Nummikoski PV, Golub LM. Doxycycline effects on oral bone loss in postmenopausal women. J Dent Res. 2001; 80: (special issue A), abstract no. 159.
90. Crout RJ, Lee HM, Schroeder K, Crout H, Ramamurthy NS, Wiener M, et al. The 'cyclic' regimen of low dose doxycycline for adult periodontitis: a preliminary study. J Periodontol 1996; 67: 506-14.
91. Golub LM, Lee HM, Stoner JA, Sorsa T, Reinhardt RA, Wolff MS, et al. Doxycycline effects on serum bone biomarkers in postmenopausal women. J Dent Res 2010; 89: 644-9.
92. Golub LM, Greenwald RA. Preface: clinical applications of non antibacterial tetracycline. Part II. Pharmacolog Res 2011; 64: 549-50.
93. Curci JA, Petrinec D, Liao S, Golub LM, Thompson RW. Pharmacologic suppression of experimental abdominal aortic aneurysms: a comparison of doxycycline and four chemically modified tetracyclines. J Vasc Surg 1998; 28: 1082-93.
94. Lindeman JH, Abdul Hussien H, van Bockel JH, Wolterbeek R, Kleemann R. Clinical trial of doxycycline for matrix metalloproteinase 9 inhibition in patients with an abdominal aneurysm: doxycycline selectively depletes aortic wall neutrophils and cytotoxic T cells. Circulation 2009; 119: 2209-16.
95. Schulz R. Intracellular targets of matrix metalloproteinase 2 in cardiac disease: rationale and therapeutic approaches. Ann Revs Pharmacol Toxicol 2007; 46: 211-42.
96. Meier CR, Derby LE, Jikk SS, Vasilakis C, Jick H. Antibiotic and risk of subsequent first time acute myocardial infarction. JAMA 1999; 281: 427-31.
97. Glen L. Antibiotic use and risk of myocardial infarction. Letters. JAMA 1999; 282: 1997.
98. Golub LM, Greenwald RA, Thompson RW. Tetracycline use and risk of acute myocardial infarction. Letter. JAMA 1999; 282: 1997-8.
99. Grayston JT, Kronmol RA, Jackson LA, Parisi AF, Muhlestein JB, Cohen JD. Azithromycin for the secondary prevention of coronary events. N Engl J Med 2005; 352: 1637-45.
100. Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Giugliano RP, et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med 2005; 352: 1646-54.
101. Brown DL, Desai KK, Vakili BA, Nouneh C, Lee HM, Golub LM. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler ThrombVasc Biol 2004; 24: 733-8.
102. Tuter G, Kurtis B, Serdar M, Aykan T, Okyay K, Yucel A, et al. Effects of scaling and root planing and sub antimicrobial dose doxycycline on oral and systemic biomarkers of disease in patients with both chronic periodontitis and coronary artery disease. J ClinPeriodontol 2007; 34: 673-81.
103. Payne JB, Golub LM, Stoner JA, Lee HM, Reinhardt RA, Sorsa T, et al. The effect of subantimicrobial dose doxycycline periodontal therapy on serum biomarkers of systemic inflammation: a randomized, double masked, placebo controlled clinical trial. JADA 2011; 142: 262-73.
104. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C reactive protein. N Engl J Med 2008; 359: 2195-207.